BeiGene | Treatment of Chinese Patients With B-Cell Malignancies With BGB-16673, a Burton Tyrosine Kinase-Targeted Protein-Degrader

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Beigene Study ID

BGB-16673-102

ClinicalTrials.gov ID

NCT05294731

China Drug Trials ID

CTR20220399

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Sex: All

Age: 18 Years / N/A

No Study Documents